may 15, 2016 august 2016 complimentary service of ...may 15, 2016 · audrey’s life science...
TRANSCRIPT
1
Audrey’s Life Science Meeting Picks for May 15, 2016 – August 2016
Complimentary Service of AudreysNetwork.com
May 15, 2016
*****************************************************************
Bio2Device Group, Tuesday Morning, May 17, 2016
Topic: “Early Stage Funding - Alternative Approaches for the Traditional Life Science
Company”
Speaker: Austin Walker, Co-Founder & CEO
Date and Time: Tuesday, May 17, 2016, 8:30 am
Location: Sunnyvale City Council Chambers, 456 West Olive Avenue, Sunnyvale
There is no registration or fee for morning meetings.
Topic Description
It is well known that early stage funding for traditional life sciences is tight. There are fewer
and fewer venture firms interested in the space, and proposed deals frequently have
suboptimal terms for founders. Austin discusses alternative approaches to financing and
highlights his experience declining traditional venture financing. The group will take a dive
into world of angels, micro-VC funds, incubators/accelerators, family funds, non-
dilutional/government, strategic financing, traditional venture financing, and more.
Discussion and audience involvement will be encouraged.
Speaker Bio
Austin Walker combines a unique blend of executive, engineering, medical, and international
experience. He co-founded a medical technology company - recruiting a team with over $3B
prior product sales, oversubscribing desired levels of financing, and achieving product
development milestones in 1/3 the time of competitor medical technology companies. He
graduated amongst the top of his class as a biomedical engineer from Northwestern. He was
on track to graduate from UCSF medical school with highest honors, but formally withdrew
to focus on company development.
*******************************************************
NCC-AWIS, Tuesday Evening, May 17, 2016
Event: Annual Awards and Recognition Banquet
Keynote Address Speaker: Susanne Lindgren, PhD, professor at Cal State
University, Sacramento and was the 2015 Judith Pool Award recipient.
Date and Time: Tuesday, May 17th: 6:00pm - 9:30pm
Location: Dominic's at Oyster Point: South San Francisco
Advance RSVP required
Event Description
The AWIS Northern California Chapters' Annual Awards & Recognition Banquet is
approaching. We cordially invite you to join us for a lovely dinner party and inspiring
evening. This annual event, hosted by AWIS-NCC brings together four chapters to celebrate
three distinguished women scientists being recognized for mentorship. Early bird ticket
special available through May 9th.
RSVP for the ceremony today!
Fees and registration at http://www.brownpapertickets.com/event/2533796
2
Join us for our annual celebration of women in science:
Mingle, enjoy wine and appetizers, and then stay for a lovely buffet dinner
and ceremony
Reconnect with friends and make new ones from around the bay
Be inspired by personal stories of excellence in science and mentoring
Leilani Miller, PhD, of Santa Clara University will receive the 2016 Judith Pool Award.
Wendy Fantl, PhD, of Stanford University will receive the 2016 Ellen Weaver Award.
Tracy Lin, RPh, of Johnson & Johnson will receive the 2016 Sherrie Wilkins Award.
Reserve your banquet ticket now. Registration is $40 through May 9th, and $50 May 10-16.
No onsite registration.
**************************************************************
BioPharmaPM, Wednesday, May 18, 2016
Event: “2016 BioPharmaPM annual conference: "Strategic and Business Management,
Leadership, & Technical Project Management: Leveraging the PMI Talent Triangle in
BioPharma"”
Date: Wednesday, May 18, 2016.
Details and registration at https://www.biopharmapm.org/conference
We are also taking advantage of technology and holding the conference at two locations via
videoconference to enable and encourage greater participation. Our sponsors for the event,
Genentech and Pfizer, have graciously offered to host the event at their facilities in South
San Francisco and La Jolla, California, respectively. We will have speakers and networking at
each site, so if you are local to these facilities, or able to travel, please plan on attending.
The registration fee is $299 for the one-day conference and for 2016, we are including an
annual membership to the organization in the cost. Registration is a two-step process on
our website: 1) Pay for the conference and 2) Complete the registration. Following
payment, please "Register for the Conference" to register your name so you receive all
updates as the conference date approaches.
The conference will be held on May 18th at two locations via videoconference. Our sponsors
for the event, Genentech and Pfizer, have graciously offered to host the event at their
facilities in South San Francisco and La Jolla, California, respectively. We will have speakers
and networking at each site, so if you are local to these facilities, or able to travel, please
plan on attending. Given our sponsors' generosity, Genentech and Pfizer colleagues will be
eligible for a significant discount on the registration fee. If you are a colleague at a
sponsoring organization, please contact me directly at [email protected] on
how to access this discount.
Registration is limited to 100 participants per location, so register soon! We look forward to
seeing you at the conference!
*****************************************************************
EMBS, Wednesday Evening, May 18, 2016
Topic: “Digital Medicines Provide Physicians With Insights into Patient Medication-taking
Patterns and Physiologic Response, Enabling Efficient Therapy Optimization”
Speaker: Mark J. Zdeblick, Ph.D., Co-Founder, Chief Technology Officer, Proteus Digital
Health, Inc.
Date and Time: Wednesday, May 18, 2016, 7:30 PM
3
Location: Room M-114, Stanford University Medical School
Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations)
Topic Description
Proteus Digital Health is a company with an innovative solution for activating patients and
helping improve medication adherence. This novel digital Medicines as a Service (MaaS)
offering is called Discover. Discover utilizes sensor-enabled pills and small wearable patch
that unlocks comprehensive data about medication adherence and clinical effectiveness,
empowers more meaningful conversations between patients and caregivers, and delivers
actionable insights about entire healthcare populations. Discover and patient and physician
reaction will be described in detail. The talk will conclude with highlights from recently
announced (ACC, April 2016) cluster randomized trial that revealed that patients with
uncontrolled hypertension and diabetes who used Proteus Discover achieved statistically
significant reduction in blood pressure (BP) and low-density lipoprotein-cholesterol (LDL)
and were more likely to achieve their BP goal than usual care.
Speaker Bio
Prior to co-founding Proteus Digital Health, Mark Zdeblick served as the chief technology
officer for the optical switch group at K2 Optronics. Dr. Zdeblick is also founder, director and
past chief technical officer of Redwood Microsystems, developer of the world’s highest
performance microfabricated valves and electro-fluidic integrated circuits. While working in
Professor Calvin Quate’s engineering group at Stanford, Dr. Zdeblick invented the
microfabricated cantilever beam with an atomically sharp tip that enabled atomic force
microscopy. He holds a B.S. in civil engineering (Tau Beta Pi, Phi Eta Sigma) and a B.A. in
architecture, both from the University of Illinois, and an M.S. in aeronautics and
astronautics and Ph.D. in electrical engineering from Stanford University. He is named as an
inventor on over 300 issued patents and is an advisor and/or lecturer to engineering
programs at Rice University, Stanford University, and UC San Diego.
*****************************************************************
GGPF Dinner, Wednesday Evening, May 18, 2016 Lecture: "Polymer and Mixed-Matrix Membranes for Gas Separations" Speaker: Dr. Zachary P. Smith, Department of Chemistry,University of California, Berkeley Date and Time: Wednesday, May 18 6:00 PM social hour 7:00 PM dinner 8:00 PM presentation Location: Michael's at Shoreline, 2960 N Shoreline Blvd., Mountain View Cost: Employed/postdocs: $30 early registration, $35 regular registration; Unemployed/retired/students: $15 early registration, $20 regular registration Free if you attend just the lectures at 8:00 PM (but please let us know for headcount) After deadline: Registration not guaranteed, so contact us Late fee applies if space available -- $40 regular/employed, $25 unemployed/student/retired Deadlines for registration: End of discounted advance registration 11:59PM, Friday, May 13 End of regular (full-price) registration 5PM Tuesday, May 17 Register at www.GGPF.org<http://www.GGPF.org> (PayPal is enabled if desired) Because we must pay the restaurant for the ordered meal, we must ask no-shows to pay for their reservation.
4
However, penalty-free cancellations are allowed up until the deadline for reservations (Tuesday, May 17, 5:00 PM). PLEASE NOTE: We accept cash or checks at the door, but are unable to accept payment by credit card at the event. You may pay at the door. Checks may be made to "GGPF" Discounted advance registration ends 11:59PM, Friday, May 13 Final full-price registration ends 5PM, Tuesday, May 17 Please register on the web page Or, if necessary, contact: Len Radzilowski 650-361-3264 [email protected]<mailto:[email protected]> Topic Description In the U.S. today, there are over 40,000 distillation columns performing more than 200 separations, which account for 49% of the total separation energy consumption in industry. Other energy intensive and environmentally harmful processes such as amine absorption are also used on a large scale, so a need exists to find alternative separation technologies. Of particular promise are membrane-based separations, which, unlike distillation, circumvent significant energy requirements for phase changes, and, unlike absorption, operate in continuous flow, thereby avoiding regeneration steps. Here, a broad overview on membrane-based gas separations will be presented, with an emphasis on current and emerging applications and materials. Next, three strategies will be presented on methods for designing new materials for efficient and productive separations. From a polymer perspective, two approaches will be presented, one on manipulating polymer morphology to control diffusion rates, and the other on using perfluorinated polymers to manipulate polymer-penetrant interactions. Finally, an alternative strategy will be presented, whereby highly selective inorganic particles are dispersed into a polymer matrix to improve transport performance in a platform of materials known as mixed-matrix membranes. Speaker Bio Zachary P. Smith is currently a postdoctoral scholar in the Department of Chemistry at the University of California, Berkeley. He earned his bachelor's degree in Chemical Engineering from the Penn State Schreyer Honors College, conducting research with Prof. Hank Foley on porous carbon-based materials for applications in oxygen enrichment. Zach completed his graduate training in Chemical Engineering under the guidance of Profs. Benny Freeman and Don Paul at the University of Texas at Austin, developing structure/property relationships for gas diffusion and sorption in polyimides, perfluoropolymers, and related materials. His postdoctoral training, under the guidance of Prof. Jeffrey Long, focuses on designing coordination solids (i.e., metal-organic frameworks) for selective adsorption-based separations. Zach has co-authored over 20 peer-reviewed publications and has been recognized with several awards including the Department of Energy Office of Science Graduate Fellowship and the ACS Excellence in Graduate Polymer Research Award. He was also selected as a U.S. delegate to the Lindau Nobel Laureate Meeting on Chemistry in 2013.
***************************************************************
JLABS, Thursday, May 19, 2016
Event: “WORKSHOP 3 | Lessons Learned: The IPO process from battle tested
Veterans”
Speakers:
Linda Bain | Chief Financial Officer, Codiak BioSciences read bio»
Isaac Ciechanover | President & CEO, Atara Biotherapeutics read bio»
[moderator] Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte &
Touche LLP
Date and Time: Thursday, May 19, 2016, 8:15 am
5
Agenda:
8:15 AM | Registration Opens, Breakfast and Networking
9:00 AM | Panel and Q&A
10:30 AM | Closing remarks and networking
11:00 AM | Program Close
Location: JLABS @ SSF, 329 Oyster Point Blvd - 3rd Floor, South San Francisco, CA
Day 3 Fees: $20 | General Public: $35 | At the door
Register at http://www.eventbrite.com/e/how-to-ipo-series-tickets-
20106147027?aff=blast#Day3
Event Description
There is nothing like experience! The final event in our 3 part IPO series with Deloitte
& Touche, LLP brings in two high profile C-level executives. They have gone through
the IPO experience and as IPO journey's go, their paths were different.
This breakfast event will take a look at two companies that recently went through
successful IPO's. The company leaders will share their insights from firsthand
experience on issues ranging from preparation to execution.
Topics include:
Hiring the right professional team
Managing the Board
The roadshow
Pricing, timing and market conditions
The surprises, pitfalls and lessons learned
With plenty of time for Q&A
Join us for an insider's look at the IPO!
Speakers' Biographies:
Linda Bain | Chief Financial Officer, Codiak BioSciences
Linda Bain joined Codiak from Avalanche Biotechnologies where, as chief financial
officer, she led a successful IPO and follow-on financing. She previously served as
vice president of finance, business operations and treasurer at Bluebird Bio. Ms. Bain
has held senior roles at Genzyme Corporation, including vice president of finance,
global manufacturing and operations and vice president of finance of Genzyme
Genetics. Earlier in her career, she served in senior finance roles at Fidelity
Investments and AstraZeneca Pharmaceuticals and as an auditor at Deloitte &
Touche.
Isaac Ciechanover, M.D. | President & CEO, Atara Biotherapeutics
Dr. Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion
to improve the practice of medicine. Motivated by the belief that the majority of
medical discoveries still lie ahead, he has dedicated the past 20 years to working
with entrepreneurs and life sciences organizations to advance medicine through
innovation and technology. He founded Atara Biotherapeutics in August 2012.
Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield &
Byers. Earlier as Celgene's Executive Director for Business Development, he
spearheaded the company's venture capital efforts and led licensing and M&A
activities with an aggregate value of more than $6.7 billion. Also at Celgene, he was
Global Project Leader for the company's first clinical-stage biologic therapy. Isaac has
also held business development and venture capital roles at Amylin Pharmaceuticals,
Pequot Ventures' healthcare practice and Pfizer. Intellectually curious (and
6
undeterred by student debt), Isaac holds a B.A. from Stanford University, an M.Phil.
in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical
College and an M.B.A. from Harvard Business School. For fun, he enjoys cycling,
scuba diving and building Lego with his two children. His all-time favorite albums are
Pink Floyd's "The Dark Side of the Moon," Radiohead's "OK Computer" and Ruggero
Leoncavallo's Italian opera, Pagliacci, with Herbet Von Karajan conducting.
Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP
Angela has 20 years of experience serving both public and private companies with a
focus on the life sciences industry. She works with companies in all stages of growth,
from start-ups to SEC registrants. Her technical background includes complex
accounting issues such as revenue recognition, equity, derivatives, stock-based
compensation, and acquisitions. Angela has been involved in financing and M&A
transactions, including initial public offerings, offerings in leveraged buyouts, and
several secondary shares offerings. She has extensive international experience and is
a certified public accountant in the United States and the United Kingdom. Angela
also served as a CFO before returning to public accounting in 2003.
**********************************************************************
QB3, Thursday Mid Day, May 19, 2016
Topic: “How to Navigate US Immigration Law for Biotech Entrepreneurs”
Speakers: Norman Plotkin and Atessa Chehrazi, partners at the immigration law firm of
Jackson & Hertogs
Date and Time: Thursday, May 19, noon to 1:00 pm
Location: Room 160, Helen Diller Bldg. (1450 Third St.), UCSF Mission Bay
Fee: General Admission - $10
Register at http://www.eventbrite.com/e/qed-norman-plotkin-and-atessa-chehrazi-how-to-
navigate-us-immigration-law-for-biotech-entrepreneurs-tickets-
21686104723?mc_cid=1a27eae361&mc_eid=cb4c38a44a
Topic Description
Biotech companies want to hire talented employees with the right skills but many
candidates may need to be sponsored by the employer because they might not be US
citizens or permanent residents. What are the options for entrepreneurs starting up
businesses? How can a founder establish an immigration policy to attract and retain the best
and the brightest? What visa options are available and how best to navigate through US
immigration laws? Norman Plotkin and Atessa Chehrazi, partners at the immigration law
firm of Jackson & Hertogs, will explain how the most common visas such as H-1B, J-1, and
TN work and will discuss recent developments in immigration law including changes to the
F-1 STEM OPT work authorization.
What you'll learn
• How US immigration laws work and what the differences are between the H-1B, J-1,
O-1, and TN visas
• How to establish an internal immigration program or navigate an employer’s
immigration program
• The most recent developments in immigration law
Speaker Bios
Norman became a partner in February 2002. Throughout his career, Norman has
been active in AILA. Previously, he served as the editor of the Gold Book, a resource
for practicing immigration law in California, and as co-editor of the Western Region
Directory for the Immigration Practitioner. He was also liaison for the Northern
7
California AILA Chapter to both the California Service Center and the U.S.
Department of Labor. In addition, he was a member of the national AILA/California
Service Center liaison committee and previously served on the national
AILA/Department of Labor liaison committee. He has also lectured at seminars and
conferences including national AILA Conferences, the BIO International Convention,
the BIO Human Resources Conference and the HR Star Conference. Norman has
received high marks in all legal directories, including a listing in the Best Lawyers in
America. He is fluent in Spanish.
Atessa has been a partner at Jackson & Hertogs since April 2013 and an
associate/senior associate since July 2000. She was previously an associate at
Maggio & Kattar in Washington, D.C. from 1996 to 2000. She has held several
volunteer roles within the American Immigration Lawyers Association (AILA) during
her career. For AILA’s Northern California Chapter, she has served as Chair, Vice-
Chair, Treasurer, U.S. Citizenship & Immigration Service (USCIS) liaison, and
Customs & Border Protection (CBP) liaison. On a national level, Atessa served on
AILA’s USCIS Headquarters and Benefits, Administrative Appeals Office (AAO), and
Department of Labor (DOL) liaison committee. In addition, Atessa has served on
AILA’s Business Immigration Advocacy, Issues, and Due Process & Civil Liberties
committees, as well as several conference committees. She has served as a board
member of the Iranian American Bar Association Northern California chapter since
2009 and is incoming President of the chapter. She is a member of the Bar
Association of San Francisco, and the National Lawyers Guild. She has authored
several articles published in AILA Handbooks. Atessa has presented at national and
regional AILA conferences. Atessa has been highly reviewed in legal directories,
including selection as a Northern California “Super Lawyer” (2010-2012), and listing
in the International Who’s Who of Corporate Immigration Lawyers (2011-2015).
*************************************************************************
Clark Seminar, Thursday Mid Day, May 19, 2016
Event: In vitro Vascularized Constructs as Models of Metastatic Cancer
Date and Time: May 19, 2016, noon
Location: Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
Small Lunch Served At 12:00; Lectures Begin At12:15
Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360
********************************************************************
ACRP Northern California Chapter, Thursday Evening, May 19, 2016
Topic: Spotlight on Site/Sponsor Collaborations: Soutions to 5 Key Issues
Speaker: Christine Pierre, President, Society for Clinical Research Sites
Date and Time: Thursday, May 19, 2016 - 6:00 – 9:00 pm
Fee: Fee: NCC ACRP member $ 5
ACRP member $25
Non-member/public $30
XOMA, ACRP Membership NOT required.
Registration Link:
http://www.acrpnet.org/GetInfoFor/USChapters/NorthernCalifornia/Upcoming...
EVENT REGISTRATION closes Thursday , May 12, 2016, 11:59PM Eastern Time
Register NOW to assure admission
Walk-in registration: if seats available & add $5 to below registration fee
8
Registration Link:
http://www.acrpnet.org/GetInfoFor/USChapters/NorthernCalifornia/Upcoming...
1.5 ACRP, CBRN, and CME CONTACT HOURS are approved
Purchase contact hours with online registration or up to 14 days after event
CHAPTER MEMBERS FREE – included in your online registration
ACRP member $15
Non –member/public $30
Bring your email confirmation to the event. Please notify Event Manager of cancellation. No
refunds or transfers.
To receive contact hours: Purchase the contact hours online only with registration or up to
14 days after the event, sign-in at event registration, and attend the program. Go to
http://www.acrpnet.org/ , logon as member or guest, go to “Learning Portal” 1-30 days
after the event to complete the evaluation and receive the certificate.
Description:
Sites, sponsors, and CROs daily live the challenges to meet study enrollment targets, stay
within budget, and maintain quality and sustainability. How can we be smarter and swifter
in operationalizing increasingly complex protocols within available resources?
Christine Pierre presents stunning data on the operational challenges and new approaches
to solutions from sites, sponsors, and vendors supporting them. Hear about several recent
surveys – 86% sites failed to recruit on time; doubling of protocol complexity in the last 15
years; 25-50% screen fail rates; 11% sites non-enrolling and 37% under enrolling; 60%
sites report a negative impact from RBM including decreased quality; 60% sites have less
than 3 months operating cash.
Hear about best practices and new ideas for sites and sponsor to collaborate on solutions to
5 key issues: study opportunities, site feasibility process as a 2 way street, contracts &
budgets, risk based monitoring, and sponsor payments.
Learning Objectives:
• Describe practical site/sponsor collaborations for successful clinical trial operations
• Discuss site sustainability metrics
• Describe site/sponsor initiatives producing results such as universal contract language,
site scorecard and investigator payments
ACRP online registration/contact hour purchase questions: [email protected]
NCC Event questions: Gina Hashem [email protected] or Caroline Cooper
Free parking in front of XOMA main entrance and behind building if front lot is full.
Please see our website for our calendar and more information
http://www.acrpnet.org/GetInfoFor/USChapters/NorthernCalifornia.aspx
********************************************************************
BioPharma Consortium, Friday Morning, May 20, 2016
BioPharma Consortium Breakfast Briefing: Must-Know Finance Concepts for Life Sciences
Valuations: Good, Bad, & Most Effective
Speaker: John Selig, Co-Founder and Managing Partner, Mavericks CapitaDate and Time:
Friday, May 20, 2016, 8:00 am
Location: 475 East Grand Avenue, South San Francisco, 94080 Room 42-1E
lRegistration closes @ 9 am on May 18 Pricing: No cost, but online registration required at:
http://www.biopharmaconsortium.com/bay-area-events/
Topic Description
This talk will present an introduction to the key concepts and most common methodologies
used to evaluate life sciences assets.
If you are an entrepreneur interested in raising financing, licensing an asset or selling your
company; a private investor who wants to estimate and negotiate start-up share value; or
any other professional who is active in the investing sector, you'll benefit from this overview
9
of the key concepts used in life sciences valuation discussions. Portfolio and program
managers who iteratively perform valuation of their assets in mid to late stages of drug
development will also benefit from this talk.
Topics covered include:
The various valuation methodologies used to assign a value to life science businesses and
assets
The methodologies used in particular by pharma partners and venture capitalists
An explanation of three fundamental concepts in valuation: risk-adjusted value, cost of
capital and present value
Speaker Bio
John advises life sciences companies on M&A, licensing and financial strategy and speaks
frequently on topics in valuation, deal term benchmarking, and strategy. Additionally, he
teaches the Valuation and Finance module at BIO’s Executive Management Training course
for BD professionals each year, and he will be teaching the Valuation module at Stanford
Medical School’s Entrepreneurship Program.
Prior to joining Mavericks, John was a Managing Director at Woodside Capital Partners, a
boutique investment bank. Previously, he was a management consultant, first at Strategic
Decisions Group and later at Keelin Reeds Partners, where he advised both top 20 pharma
and medtech companies as well as dozens of VC-backed and small- to mid-cap life sciences
companies on M&A, licensing strategies, portfolio management, valuation and strategic
direction. John has extensive experience in applying licensing and M&A data to inform
product strategy and provide ongoing support during deal negotiations, which has yielded
market-value deal terms for dozens of assets. John also combined his expertise in valuation,
deal term benchmarking and decision analysis with his background in law to help companies
make optimal decisions in litigation and settlement.
Prior to consulting, John was an attorney with Weil, Gotshal and Manges LLP, where he
focused on M&A and corporate finance. John holds a JD from Stanford Law School, where he
was an Associate Editor of the Law Review, and a BA, magna cum laude, from Brown
University, where he was a member of Phi Beta Kappa. (FINRA 24, 63, 79)
*************************************************************************
BioScience Forum, Wednesday Evening, May 25, 2016
Topic: "Recent Trends in the Biopharma Financing and Licensing Market"
Speaker: Chris Ehrlich, Managing Director , Locust Walk Partners
Date and Time: Wednesday, May 25, 2016 6:00 PM - 9:00 PM
Location: The Holiday Inn, 275 S Airport Blvd, South San Francisco, California 94080, USA
6 pm - 7 pm networking
7 pm - 8 pm dinner
8 pm - 9 pm presentation
Event Registration ($3 service fee will apply)
Pre-Registration $50.00
On-Site Registration $60.00
Pre-Registration ends Monday, May 23rd, at 9 pm
Cash or check accepted on the day of the event
$10 discount for full-time students
Register at https://www.cvent.com/events/bioscience-forum-chris-ehrlich-locust-walk-
partners/registration-3a0bf21203ee4b368d1cda29b7ff1bc5.aspx
Or you can pay with a check made out to "BioScience Forum" and sent to:
BioScience Forum
1442A Walnut Street, #308
Berkeley, CA 94709-1405
Please do not mail checks later than Thursday, May 19th
10
If paying with check, do not complete online registration with Cvent
Topic Description
Three years of strong financial performance in healthcare have generated over $50 billion in
potential value back to investors. Last year saw the most capital invested in healthcare
companies compared to any other year. The key driver in this performance, record
investment in biopharma, saw the largest share of crossover investment by non-traditional
biotech investors participating in large mezzanine rounds. The past three years have also
seen the largest sustained and most prosperous IPO bull market in healthcare, but the IPO
markets have dipped in the beginning of the new year.
When public markets taper off, we start to see spikes elsewhere, such as in partnering
activities. Total M&A deal values have reached a decade-high, and partnering deals spiked
both in number and value toward the end of 2015 into 2016. Licensing deals have also seen
an upward trend in value, with up-front payouts increasing for large and small deals alike.
The overall outlook for biopharma is positive, as these exits and successes have led to
higher returns and greater investor confidence. Timely and successful fundraising cycles
mean venture healthcare has enough capital to support existing investments and new
financings, which will reinforce biotech companies as the IPO market declines and non-
traditional crossover investors pull away.
Chris Ehrlich will analyze these and other key trends and data from 2015 in the financing
and licensing markets of biopharma, and provide his outlook on the opportunities and
challenges the biotechnology industry is facing in 2016.
Speaker Bio
Chris Ehrlich is a Managing Director and Head of the West Coast office for Locust Walk
Partners. He has significant biotechnology industry and venture capital experience. Since
joining Locust Walk in 2013, Chris has been involved with leading multiple transactions for
emerging biopharmaceutical companies.
Prior to Locust Walk, he was a Managing Director at InterWest Partners. He previously
served on the boards of KAI Pharmaceuticals as the Lead Director (acquired by Amgen),
Biomimetic Therapeutics, Inc. (acquired by Wright Medical Technologies) and Xenon
Pharmaceuticals. He was also a founder and board member of Carbylan Therapeutics. At all
four companies, he sat on the Transaction Committees of the Board of Directors where he
oversaw numerous business development deals.
Prior to joining InterWest, Ehrlich was director, licensing and business development at
Purdue Pharma, a private pharmaceutical firm based in Stamford, CT where he was
responsible for developing a biologic oncology franchise.
Prior to joining Purdue, Ehrlich worked in business development at Genentech, in venture
capital at The U.S. Russia Investment Fund, and in biotechnology strategy development at
LEK Consulting.
He has an undergraduate degree, cum laude, from Dartmouth College and an MBA from the
Kellogg School of Management at Northwestern University.
He currently serves on the Board of Directors of Prostate Management Diagnostics, Inc. and
on the Advisory Boards of Innovations and New Ventures at Northwestern University and
the Peter Michael Foundation, where he is a Senior Advisor. He is also a member of the
Young Presidents Organization.
11
He is a registered rep with FINRA, holding both his Series 79 and 63 licenses.
**********************************************************************
Bio2Device Group, Tuesday Morning, May 24, 2016
Topic: “Green Chemistry Global Adoption: Its challenges, advances and opportunities”
Speakers: Neelam Vaidya and Jose Castanon , CEO and Marketing Executive, ViridisChem Inc.
Date and Time: Tuesday, May 24, 2016, 8:30 am
Location: Sunnyvale City Council Chambers, 456 West Olive Avenue, Sunnyvale
There is no registration or fee required for morning meetings.
Topic Description
In 2014, Neelam and Rahul Vaidya cofounded ViridisChem Inc. with the mission to develop a
portfolio of software solutions that will provide all the information and analysis capabilities
scientists would need to practice “green chemistry” within their everyday research, that will
result in environmentally friendly product development processes that are greener, safer, and
economical. To enable this goal, the company has built in-house and proprietary
- chemical database with over 60 million chemicals,
- citation database with over 20 million citations and patents,
- reaction database with over 10 million reference reactions
It recently launched its first product Green Pocketbook that is being used both as an educational
tool and as a reference guide by universities and industry scientists for their day-to-day research
needs. It provides full chemical and toxicological profiles of chemicals, and offers “green
scores” based on these properties through easy to understand visual charts. With inclusion of
chemicals relevant to most industries, and by providing the most comprehensive information
about chemicals in a very easy to use and understand manner, Green Pocketbook is proving to be
a “must have” software solution for scientists from most industries for their day-to-day work.
During this 1-hour interactive session, the presenters will discuss:
- Green Chemistry Global Revolution: What is it, when did it start? Why is there a global and
mandatory adoption enforced by the governments?
- Current status and advances by different industries
- Roadblocks that are stopping companies from adopting green-aware research
- Challenges and Opportunities and solutions available today
- Specific needs of different industries and how are we addressing them?
- ViridisChem Solutions
- Issues surrounding “green data” and “green scores” and relationship between toxicological data
and green scores
- Green Pocketbook Product Demo
Speaker Bios
Neelam Vaidya is a serial entrepreneur with over 25 years’ experience in both high-tech and bio-
tech industry. In past she was the founder and CEO of a biotech company ChiroSolve, Inc. that
offers products and services that define chiral resolution method for optically active and hard-to-
separate chiral molecules. Neelam was also the founder of Software Company called Perfect
12
Solutions that offered enterprise software products for high-tech industry. Before her
entrepreneur career, Neelam has lead number high-profile enterprise infrastructure projects at
companies like Sun Microsystems, IBM, NASA, etc. She has M.S. in Computer Science and
B.S. in Chemistry.
Jose Castanon is a marketing professional with over 15 years of experience in medical
technology and devices. He specializes in growth strategies and bringing new technologies to
market. Prior to ViridisChem Jose was the Director of Marketing for Omnicell, where he led all
North American marketing activity for the Medication Automation and Analytics business line.
Jose has held commercial leadership roles at Philips Healthcare, Roche and Johnson and
Johnson. He holds a BS in Biology from the University of Puget Sound and an MBA from
Pepperdine University. *************************************************************
HBA, Thursday Evening, May 26, 2016
Event: “HB8 Dine-Around: The State of International Women's Health Today with Sally
Stephens”
Featured speaker
Sally Stephens
Senior vice president, corporate development, Medicines360
Date and Time: Thursday, May 26, 2016 5:30 - 6:15 PM Networking and appetizers 6:15 - 6:30 PM HBA welcome 6:30 - 7:15 PM Dinner and discussion led by Sally Stephens 7:15 - 8:00 PM Q&A discussion, dessert and networking Location: Giant Creative Agency, 1700 Montgomery Street #485, San Francisco, CA 94111 Registration information Event is open to: HBA members only Online registration deadline: May 24, 2016 Onsite (walk-in) registration: Is NOT allowed Member rate: $35 until May 18, 2016 $45 after May 18, 2016 Space is limited to 20 registrants. Cancellations/refunds Is this event refundable? Yes If yes, requests must be submitted in writing to [email protected] by May 24, 2016; no refunds are available after this date. Registration and information at https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=1EC2240B-52F8-E511-998D-0050569C00A7
Event Description
May 8 - 14 is National Women's Health Week. As the department of health and human
services and organizations rally to help US women understand the steps they can take to
improve their health, it's hard to not think about the majority of women internationally who
lack access to the basic health services we take for granted in our own county.
Did you know?:
• The number of women worldwide who had an unmet need for modern contraception
in 2012 was 222 million
13
• In Africa, only 29 percent of women of reproductive age use modern contraception
and the average number of children per woman is 4.7
• 40 percent of girls in sub-Saharan Africa are married before the age of 18
• There are 1.8 billion young people in the world right now (ages 10-24)... 600 million
are adolescent girls. Never before has there been so many young people.
Join us for an engaging dinner discussion with Sally Stephens, senior vice president,
corporate development at Medicines360, as we take a look at the state of women's health
globally. For organizations like Medicines360, whose mission is to expand access to
medicines for women regardless of their socioeconomic status, insurance coverage or
geographic location, the key is to innovate on many different levels in order to meet the still
unmet need in global women's health today.
**************************************************************
WIB Webinar, Thursday Afternoon, May 26, 2016
National Webinar: “Raising Capital for Rising Companies”
Heather Smith, Managing Director, Head of Private Financing Solutions, Sagent Advisors
Date and Time: Thursday, May 26, 2016
1:00 p.m. – 1:45 p.m. EST Presentation by Heather Smith
1:45 p.m. – 2:00 p.m. EST Q&A
Pricing Information
Members: Free
Non-Members: $15
Registration Deadline
May 25, 2016
Register at http://www.womeninbio.org/eventdetails.aspx?EventId=28822
Webinar Description
Regardless of whether one works in industry or academia, each of us plays a role in the
financial health of our organizations. From grant writing to private equity funding, there are
reasons behind the success of those who secure the funding.
Join us as Heather Smith, Managing Director, Head of Private Financing Solutions, Sagent
Advisors, discusses healthcare and technology trends and forecasts, as well as provides
insights into successful financing strategies. Heather will also discuss what makes a good
solid business, and what we need to know about market trends that impacts all of us - from
payer payments, adoption and approval processes, and reimbursements. Attendees will
have the opportunity for Q&A at the end of the presentation to have their questions
answered directly by Ms. Smith.
Speaker Bio
Heather leads the firm’s Private Financing Solutions practice. She has over 19 years of
experience in the equity and debt private placement industry, raising approximately $12
billion in private placements for companies in the U.S., Europe, South America and Asia.
Before joining Sagent, Heather was a Partner and Head of Private Placements at Greentech
Capital Advisors where she originated, structured and placed equity, mezzanine and senior
debt capital for domestic and international private companies in the sustainability sector,
including a $1.25 billion equity and project financing for GreatPoint Energy and a €463
million recapitalization and growth financing for agri.capital. Before Greentech Capital
Advisors, Ms. Smith was the Head of the Structured Private Placement Group at Deutsche
Bank Securities, Inc. raising significant equity and mezzanine capital for private companies
utilizing highly complex, customized financing structures. Prior to founding the Structured
Private Placements Group at Deutsche Bank, she was a Director and Chief Operating Officer
for the Private Placement Group at Credit Suisse Securities and Donaldson, Lufkin and
14
Jenrette. While at Credit Suisse / DLJ, she was fundamental in raising equity and/or
mezzanine for over 100 clients. Prior to working at CS, she was in the Private Placement
Group at Prudential Securities. She began her career at First Chicago Corporation (now part
of J.P. Morgan) where she was selected to participate in a multi-year management
executive training program and traded Foreign Exchange forward, options and futures.
Heather received her Master of Business Administration degree in Finance, International
Studies and Marketing with distinction from J.L. Kellogg Graduate School of Management at
Northwestern University and her Bachelor of Arts degree, cum laude, in Economics from
Harvard University.
**************************************************************
Rosenman Institute, Thursday Early Evening, May 26, 2016
Topic: “D-Series:How to Commercialize and Scale Your Product for Global Health Markets”
Speaker: Krista Donaldson, CEO of D-Rev. "Brilliance,"
Date and Time: Thursday, May 26, 2016
5:00-6:00 pm Sign-in & reception
6:00-7:00 pm Talk and Q&A
Location: UCSF Mission Bay, Byers Hall, Second Floor "Library"
Space is limited.
Fee: General - $10
Register at http://www.eventbrite.com/e/d-series-krista-donaldson-d-rev-how-to-
commercialize-and-scale-your-product-for-global-health-tickets-
25241228193?mc_cid=6af28609b2&mc_eid=cb4c38a44a
Topic Description
The D-Series is our forum on medical device development in the Bay Area. Join us to learn
about the latest technology and meet leaders in the field.
Bringing a device to the US market is challenging. But if you’re developing a solution for
patients around the world, the challenge is even bigger. Join us to hear from Krista
Donaldson, CEO of D-Rev. "Brilliance," D-Rev's phototherapy device for severely jaundiced
newborns, has helped doctors in 40 countries treat more than 130,000 babies. Krista will
discuss how D-Rev is developing new products based on the lessons learned
commercializing and scaling Brilliance.
Speaker Bio
Krista Donaldson, PhD, has driven innovation in product design, engineering, and
international development for more than 15 years. As D-Rev’s CEO, Krista’s has led the
release of Brilliance, a revolutionary technology treating neonatal jaundice, and the
ReMotion prosthetic knee. Her leadership has won Krista acclaim as one of Fast Company’s
Co.Design 50 Designers Shaping the Future, a TED speaker and a World Economic Forum
Technology Pioneer. She has also been a Rainer Arnhold Fellow and a Pop!Tech Social
Innovation Fellow.
***********************************************************
Bio2Device Group, Tuesday Morning, May 31, 2016
Topic: “How to Take a Medical Device from Concept to Market Without Losing Your Shirt “
Speaker: John N. Hendrick ,President & CEO, Mynosys
Date and Time: Tuesday, May 31, 2016, 8:30 am
Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
There is no registration or fee required for morning meetings.
15
Speaker Bio
John Hendrick has over three decades of executive experience, building both early stage
medical device companies as well as large divisions in Medical device Corporations.
During his tenure, Mr. Hendrick has participated in the development, manufacture and sales
of products in the field of Cardiology, Urology, Orthopedics and Ophthalmology.
Currently, Mr. Hendrick is president and CEO of Mynosys Cellular Devices an ophthalmic
company. Previously he was CEO of NeoVista Inc. a company in the field of Age Related
Macular Degeneration. Prior to his accepting the role of CEO with Neovista, he created the
Medical Division of Sanmina-Sci, a $12 billion dollar contract manufacturing corporation
bringing the sales of the division from 200 million to over 6oo million in two years becoming
the largest medical device contract manufacturer in world. Mr. Hendrick has been through a
successful IPO of VidaMed which led eventually to the acquisition of the Company by
Medtronic Inc. Prior to VidaMed, Mr. Hendrick held executive positions in Allergan Medical
Optics, Baxter and American Hospital Supply along with several board positions.
Currently Mr. Hendrick serves on the board of Mynosys cellular Devices Inc. as well as
advisor to Lutronic.
*******************************************************
PBSS, Tuesday Afternoon, May 31, 2016 T
Event Type: Workshop Workshop: ”Pharmacology animal models in drug development:
fundamentals, applications and case studies related to oncology, metabolic diseases,
inflammation and immunology”
Speakers: Dirk Mendel (E-Scape Bio), Stephen Gould (Genentech), Rana Samadfam
(Charles River Laboratories), Peter Havel (UC Davis), Leon Hall (Mousera)
Date and Time: Tuesday, May 31, 2016, 12:30-17:00
Location: SF Bay Area: Foster City Crowne Plaza
Registration fee (US$): Regular: $125; For vendor-show reps: $25; For unemployed &
students: $20; For major-sponsor rep (incl lunch): $0; For others, details available upon
online login.
Registration: http://www.PBSS.org
Further Information:
Registration deadline: 5/27/2016 (it will close sooner if the seating cap is reached)
********************************************************************
Clinovo Bio Talks, Wednesday Evening, June 1, 2016
Topic: "Setting up Early Stage Clinical Trials".
Date and Time: Wednesday, June 1, 2016, 6: 00 pm
Location: Hewlett Packard, Palo Alto
As always, food and wine provided :)
Register for free at: http://tinyurl.com/jnrteve*
Topic Description
I am happy to announce that registration for the next Silicon Valley BioTalks is now open.
Experts from Hallux, Apexigen, Experien Group and ClinCapture will explore some of the
challenges small and start-up biotechs face when launching clinical development programs.
This will be the 12th session of our BioTalks Chapter! **********************************************************
South Bay HBA, Saturday, June 4, 2016
Event: South Bay Coffee Chat
Location: Shoreline Lake American Bistro - 3160 N Shoreline Blvd., Mountain View, CA
To RSVP or for more information, please contact Meggin Taylor or Mary Dosunmu
16
*************************************************************************
BIO International Conference, June 6 – 9, 2016
Dates: June 6 – 9, 2016
Location: Moscone Convention Center, North, South and West Halls
Fees: Convention Access - $1,200, Members and 1,450, Non Members before April 16;
$1,400, Members and $1,750 for nonmembers after April 16 (see other package pricing at
http://convention.bio.org/register/)
*****************************************************************
WIB, Monday Afternoon, June 6, 2016
Topic: Women in Bio Plenary Event at BIO Convention: “The Influential Paths of Great
Visionary Leaders”
Speakers include: Firelli Alonso, Senior Director, Biotherapeutics and Vaccines Outsourcing,
Pfizer; Lisa Cohen, Executive Director, Washington Global Health Alliance; Renee Compton
Ryan, Vice President, Venture Investments, Johnson & Johnson; Bahija Jallal, Executive Vice
President, AstraZeneca, Head of MedImmune
Date and Time: Monday, June 6, 2016, 4:00 – 7:00 pm
Location: Clift Hotel, 495 Geary Street San Francisco, CA, 94102
Walk-Ins Accepted?
Yes*
* - Walk-ins will be accepted at the door until event capacity is reached.
Pricing Information
Members
Early bird rate through May 6, 2016: $60
Regular rate through June 2, 2016: $80
Late/walk-in rate beginning June 3, 2016*: $100
Non-Members
Early bird rate through May 6, 2016: $90
Regular rate through June 2, 2016: $110
Late/walk-in rate beginning June 3, 2016*: $130
* - Late/walk-in pricing will be effective at the door on-site.
On-Line Registration Deadline
June 3, 2016
Register at http://www.womeninbio.org/eventdetails.aspx?EventId=28587
Topic Description
In conjunction with the Biotechnology Innovation Organization (BIO) International
Convention, please join us for our signature annual WIB Plenary Event on Monday, June 6,
2016, at the beautiful Clift Hotel. Our panel of esteemed speakers will discuss critical, and
often controversial, issues affecting women in the life sciences industry, identify important
industry trends and how to act on them, and how they created their career paths. This
panel is sure to inspire and motivate both women and men to work together to support the
career development of women!
Date and Time: Monday, June 6, 2016, 4:00 – 6:00 pm
As with all WIB events, our Plenary Event encompasses an inviting and fun environment for
networking as it brings together people from all corners of the life sciences industry, and
spawns new career and business opportunities.
This event is not to be missed so register today!
*****************************************************************
BIO Career Fair, Thursday Afternoon, June 9, 2016
17
Event: BIO Career Fair
Date and Time: Thursday, June 9, 2016, 2:00 – 7:00 pm
Cost: Free
Details and registration at http://convention.bio.org/careerfair-jobseekers/
BIO is proud to announce the 2016 BIO Career Fair, Thursday June 9 from 2:00 - 7:00 pm.
As an extension of BIO’s online job board—Bio Jobs—the Career Fair will provide an
opportunity for meeting participants and top employers to discuss career opportunities..
The BIO Career Fair (is free) and will allow you access to many of the world’s leading life
science companies. A minimum of a 4-year life science degree OR a community college
biotech degree is recommended and military veterans are encouraged to apply. Details at
More information coming soon!
*********************************************************************
qb3, Thursday MidDay, June 9, 2016
Register now for the QB3 Spring 2016 NSF SBIR Bootcamp
UCSF Mission Bay
Two one-hour classes. Location: Genentech Hall N-114, UCSF Mission Bay
First session: Thursday, May 5
Second session: Thursday, June 9
Please note that this workshop will exclusively focus on the specifics of the NSF
application and will not cover the basic information covered in our longer course. For
this reason, we recommend that you sign up for this session if you have previously
attended the QB3 NIH SBIR workshop or have a basic understanding of the SBIR
process.
Our NSF SBIR/STTR workshop will address specific differences between the NSF and
NIH applications to successfully file a well-written SBIR/STTR grant application for
the June 16 NSF SBIR deadline (June 20 for STTRs). The course culminates in a
submission clinic that will ensure your application is correctly filed.
One or more team members from the company should be prepared to attend every
session.
Remember to bring your laptop; these will be working sessions.
Course includes
One 1-hour working session, plus one 1-hour filing clinic
Pre-submission review of specific aims by our course instructors
Session 1 will cover the application process, including registration
Session 2 will cover the upload and submission process
Schedule
Dates Time Location
5/5 (Thurs) 1:00-2:00 PM Room N-114, Genentech Hall
6/9(Thurs) 1:00-2:00 PM Room N-114, Genentech Hall
Instructor: Shauna Farr-Jones, PhD, UCSF/QB3 grant writer
Standard rate for the entire workshop: $150 per company
Discounted rate for UC affiliates, QB3 Startup in a Box members, QB3 Incubator
members, and QB3/CLSA Accelerator members: $50 for entire course per company
Teams registered for the Spring 2016 QB3 NIH SBIR workshop: $0
Have questions about QB3 Spring 2016 NSF SBIR Bootcamp? Contact QB3
*********************************************************************
18
HPLC, Sunday, June 19, 2016
Topic: “HPLC 2016 - 44th International Symposium and Exhibit on High Performance Liquid
Phase Separations and Related Techniques”
Date and Time: Sunday, June 19, 2016 , 8:30 am
Location: Mariott San Francisco Marquis
The goal of HPLC 2016 is to bring together scientists who use and develop
HPLC, capillary electrophoresis, supercritical fluidic chromatography, microfluidics, and mass
spectrometry to exchange ideas, best practices, and
latest developments. The conference program is guided by emerging trends in
separations technology and their impact on science and society.
THREE SESSION TRACKS AT HPLC 2016:
Technology: Better, Faster, Quantitative Separations
Interface to MS: Improving Information Content
BioAnalysis and Applications: Impacting Science and Society
Topics include column and stationary phase technology, interface to mass spectrometry,
microfluidic systems, capillary electrophoresis, LCxLC, QA&QC methods, QbD in separations,
and application to real world problems. A special emphasis in applications will be on
bioanalysis including:
pharmaceuticals, antibody-drug conjugates, antibody characterization, biotechnology,
proteins and proteomics, glycomics, metabolomics and lipidomics, food and nutrition, well-
characterized biologicals, biofuels, environment, and toxicology.
Also Featuring:
Tutorials, Short Courses, User Group Meetings, and Lunch Technical Sessions
For more information, visit: www.hplc2016.org
http://www.hplc2016.org/index.html
Type of Registration: Fees are posted under the "Online Registration" tab located at
www.HPLC2016.org.
Payment must be made by check or credit card payable in US Dollars and drawn on a US
bank (no bank wire transfers).
Registration is not accepted or acknowledged until payment is received.
By submitting this registration, you authorize the HPLC 2016 meeting to share your
information with attendees, etc.
Student Registrants: In order for the student rate to be accepted, must submit proof of
current full-time graduate or undergraduate, not postdoctoral, status at an academic
institution by providing both a copy of your Student I.D and a letter on university stationery
from your department chair along with the department chair contact details and email.
Email the letter and copy of the Student ID to [email protected].
All Oral and Poster Presenters: In order to present, the presenting author of each lecture
and poster must be registered as a conference attendee (not booth staff) and must
complete the registration process by paying online by April 18 to confirm intent to attend
and present at the meeting. If fees are not paid, submissions from that author will be
removed from the program.
Refund Policy: A processing fee of 20% will be collected on cancellations on or before April
1, 2016, after which the fees are non-refundable. Registration is transferable; must contact
Symposium Manager by no later than one week prior to the conference to transfer and
receive confirmation of the transfer of the registration ([email protected] or
telephone 301-668-6001).
HPLC 2016 Symposium/Exhibit Manager
Ms. Janet Cunningham
Barr Enterprises
www.LinkedIn.com/in/BarrEnterprises
19
phone 301-668-6001
www.HPLC2016.org
***********************************************************
JLABS, Tuesday Morning, June 21, 2016
Topic: “Swim with the Funds: The Story of Funding from Those Who Succeeded”
Speaker: Caleb Bell | CEO, Bell Biosystems
Colleen Cutcliffe | CEO and Co-founder, Whole Biome
Tim Hsiao | Small Business Innovation Specialist, NIH/NIAID
Casey Lynch | CEO and Co-founder, Cortexyme
[moderator] Laura Brege | Managing Director, Cervantes Life Science Partners
Date and Time: Tuesday, June 21, 2016
10:00am | Registration and Networking
10:30am | Introduction
10:35am | Panel
11:30am | Q&A
11:45am | Lunch and Networking
12:30pm | Program Close
Location: LABS @ SSF, 329 Oyster Point Blvd , 3rd Floor, South San Francisco, CA
Fees: $20
Register at http://www.eventbrite.com/e/swim-with-the-funds-the-story-of-funding-from-
those-who-succeeded-tickets-25128996505?aff=blast
Topic Description Without it your startup will not float. There are many sources of funding including Angels, VC's, governments, incubators, Pharma, friends and family, etc... but how do you get it? What source(s) are best for your company?
Topics covered:
Johnson & Johnson Innovation, JLABS is fortunate to have a breath of startups with a wide
range of funding experience, so we asked them to share their inner funding thoughts and
secrets. Joins us for a deep dive to look how current startups are succeeding at the funding
game and how they plan to continue to keep their head above water.
• Where did you start?
• How does one offer effect interest form others?
• Angel vs. Friend/family vs. VC's vs. incubators
• Seed- series A, B, and beyond when is it best to have one investor lead the round?
• Do funding methods differ depending on the product: med
device/instrument,bioinformatics software, biologic drug or therapeutic.
• The process - how many times did you get up to the plate before you got on base?
How about non-accredited investors/crowd sourcing?
Speaker Bios
Caleb has served as CEO of Bell Biosystems since co-founding the company. Under
Caleb's leadership, Bell Biosystems has been recognized by the White House for its
"Breakthrough" in life science technologies, as a 2014 Rising Star by BayBio, and as
a "biotech on the cusp of something big" by the San Francisco Business Times. Caleb
sits on the board of trustees of BayBio and founded three companies prior to Bell
Biosystems, serving as CEO of one for six years. He is a well published scientist and
named inventor on multiple issued patents. Caleb earned a Ph.D. in Biophysical
Chemistry from Stanford University, completed the Stanford University Graduate
School of Business Ignite program, and received a B.S. in Biochemistry and Molecular
20
Biology from Penn State University.
Connect with Caleb:
Colleen Cutcliffe is the co-founder and CEO of Whole Biome, an early stage
microbiome company. Colleen has over a decade of experience managing and
directing fundamental biology research teams in the academic, pharmaceutical and
biotech sectors. Prior to starting Whole Biome, Colleen served as the Senior Manager
of Biology at Pacific Biosciences, a Scientist at Elan Pharmaceuticals and a
Postdoctoral Fellow at Chicago's Children's Memorial Hospital. Colleen received her
Ph.D. in Biochemistry and Molecular Biology from Johns Hopkins University and her
B.A. in Biochemistry from Wellesley College.
Connect with Colleen:
Tim manages various initiatives, including the I-Corps program at NIAID, to
strengthen the portfolio performance of federal investments in biomedical small
business innovation research/technology transfer (SBIR/STTR). He also conducts
portfolio analysis and leads a trans-NIH working group to help shape NIH's evaluation
metrics for SBIR/STTR commercialization success. He developed his expertise in
innovation policy and public-private partnership through his prior services as an
Innovation Policy Officer (Economic Section of the U.S. Embassy in Mexico City) and
a Science & Technology Policy Fellow (American Association for the Advancement of
Science). He holds a Ph.D. in Molecular Biophysics & Biochemistry from Yale
University, and is affiliated with NIAID Division of Extramural Research's Office of
Research Training and Special Programs (Contract-based).
Connect with Tim:
Casey Lynch is the co-founder and CEO of Cortexyme, a privately funded company
developing novel treatments and diagnostics for Alzheimer's disease and other
degenerative disorders. Casey was the co-founder and Managing Director of
NeuroInsights and Aspira Biosystems. Aspira was acquired by Nanomune Inc. in
2004. Casey oversaw toxicology screening and evaluated new product opportunities
at Centaur Pharmaceuticals where she established disease model testing paradigms
for multiple sclerosis, uveitis, and other neurological disorders. Casey conducted
primate preclinical trials for Alzheimer's disease treatment at the Wadsworth Medical
Center in Los Angeles and researched the neurological basis of schizophrenia and
epilepsy at UCLA. She has worked with companies on partnering and fundraising as
well as investors to identify and profit from opportunities in commercial neuroscience
through consulting, conferences, and publications. Casey has a BS in neuroscience
from UCLA, and an MS in neuroscience from UCSF doing research in the Mobley lab at
UCSF/ Stanford University where her graduate research focused on neurotrophic
factor cell biology and neurodegenerative diseases. She has completed the
Management Development for Entrepreneurs (MDE) program of the Anderson School
of Business. Casey is on the Board of Directors of The Neurotechnology Industry
Organization, a trade association for commercial neuroscience.
[moderator] Laura Brege | Managing Director, Cervantes Life Science Partners
Laura Brege has over 25 years of executive management experience in the
pharmaceutical, biotechnology and venture capital industries. Most recently, Ms.
21
Brege was President & CEO of Nodality, Inc., a private company focused on
innovative personalized medicine approaches in oncology, immunology and immuno-
oncology. Prior to joining Nodality, Ms. Brege held several senior-level positions at
Onyx Pharmaceuticals, Inc., a global oncology company, including Executive Vice
President and Chief Operating Officer. While at Onyx, she led multiple functions,
including commercialization, strategic planning, corporate development, technical
operations and medical, scientific and government affairs. Prior to Onyx, Ms. Brege
was a General Partner at Red Rock Capital Management, a venture capital firm
investing in early stage technology companies. Previously Ms. Brege was CFO at COR
Therapeutics, helping build the company from an early stage R&D company through
commercial launch of a successful cardiovascular product. Earlier she served as CFO
at Flextronics, Inc. and Treasurer of The Cooper Companies. Ms. Brege serves on the
Board of Directors of Acadia Pharmaceuticals, Aratana Therapeutics, Dynavax
Technologies, Portola Pharmaceuticals and Pacira Pharmaceuticals. She served on the
Board of California Life Sciences Association (CLSA). Ms. Brege received her MBA
from The University of Chicago and her undergraduate degree from Ohio University,
Honors Tutorial College.
***************************************************
CLSA, Lunch and Learn, Tuesday Mid Day, June 21, 2016
Topic: “Lunch & Learn: From Millennials to Gen X: What you need to know about Retirement
Plan Management”
Speakers: Mike Foy, CFP. DCIO Investment Specialist, Putnam Investments
And Michele Giangrande, Vice President, DCIO Consultant, T. Rowe Price Investments
Date and Time: Tuesday, June 21, 2016 from 11:00 AM to 1:00 PM (PDT)
Time/ Agenda:
• 11:00am | Registration
• 11:30am – 12:30pm | Program
• 12:30 – 1:00pm | Networking
Location: 250 East Grand Ave. , Suite 26 , South San Francisco, CA 94080South San Francisco, CA Top of Form
Ticket Information
Ticket Type Sales End Price Fee Quantity
CLSA Member
Membership status will be verified
upon registration.
Jun 21, 2016 Free $0.00 Ticket Quantity Select
Non-Member Jun 21, 2016 $75.00 $0.00 Ticket Quantity Select
Register at http://www.eventbrite.com/e/lunch-learn-from-millennials-to-gen-x-what-you-
need-to-know-about-retirement-plan-management-tickets-25362533019
Topic Description
Since the inception of the 401(k) in 1980, the responsibility of saving for retirement has
slowly shifted from employers to the employee. Coinciding with that shift has alsbeen a
change in the workforce from baby boomers to increasing numbers of millennials. This has
led to a retirement readiness crisis that affects all employees - from those employees about
to retire all the way to those starting their first jobs out of college.
Join UBS’s 401(k) advisors for lunch to gain insight on how to help you meet this retirement
challenge head on. Their knowledgeable team will cover important aspects of social security
22
to help soon-to-be retirees understand how to maximize monthly benefits in addition to
strategies and tactics to help put millennials on the path to retirement success.
*************************************************************************
3rd Annual Rosenman Institute, Wednesday Afternoon, June 22, 2016
Topic: “Medical Devices Reimagined":
Date and Time: Wednesday, June 22, 2016, 1:00 – 5:30 pm
Location: Byers Auditorium, Genentech Hall - 600 16th Street UCSF Mission Bay, San
Francisco, CA 94158
Fee: Free
Register at
https://www.eventbrite.com/orderconfirmation/24493653176/518462594/AA6ItQMgY
JABjLh5CpgacVHgWRuYtSsFoA/
Topic Description
Every day, engineers integrate new technology into medical devices. But with the
pace of advances in technology and discovery, the potential for devices now far
outstrips the state of the art. It is essential for us to reimagine the possibilities.
Where better to reimagine devices than the Rosenman Symposium, held at UCSF
Mission Bay? Together, we can speed the development of exciting technologies to
improve the lives of patients.
Check out the speaker lineup below!
Speaker Bios
Adam Gazzaley, M.D., Ph.D. is Professor in Neurology, Physiology and Psychiatry at
UC San Francisco, and the Founding Director of the Neuroscience Imaging Center,
Neuroscape Lab and the Gazzaley Lab. His lab explores mechanisms of neuroplasticity
and designs, develops and validates new technologies to optimize cognitive abilities
via engagement with closed-loop systems using custom-designed video games,
neurofeedback and transcranial electrical stimulation. Dr. Gazzaley is also co-founder
and Chief Science Advisor of Akili Interactive, a company developing therapeutic
video games and Chief Scientist of JAZZ Venture Partners, a venture capital firm
investing in experiential technology to improve human performance. He has filed
multiple patents based on his research, authored over 100 scientific articles, and
delivered over 450 invited presentations around the world. Dr. Gazzaley has received
many awards and honors, most recently the 2015 Society for Neuroscience – Science
Educator Award.
Since 1998, Hanson Gifford has been a Managing Member of The Foundry, LLC. The
Foundry has created Evalve (acquired by Abbott Labs), Concentric Medical (acquired
by Stryker), Emphasys Medical, First to File, Satiety, Xtent, Cierra Medical, Ardian
(acquired by Medtronic), Cabochon (acquired by Ulthera/Merz), Miramar Labs,
Twelve, Holaira, Cotera, and Fire1. Mr. Gifford is also a founder of ForSight Labs, an
ophthalmic device incubator which has started six companies. Prior to The Foundry,
Mr. Gifford was VP of Research and Development at Heartport, Inc. Mr. Gifford is an
inventor on over 225 issued U.S. patents. He has a B.S. in mechanical engineering
from Cornell University.
Darrell Johnson joined Medtronic in 2007 and serves as Vice President and General
Manager for the Cardiac Rhythm and Heart Failure (CRHF) Connected Care business.
Darrell has built an expertise in working within the medical device industry,
identifying how wireless technologies and data systems may be applied to improve
23
patient outcomes, decrease healthcare utilization costs, and increase provider care
delivery efficiencies. His passion centers on not simply bringing technologies to
market, but the successful implementation and utilization of these technologies
within the entire healthcare system, including patients.
Bryan Larson joined Stryker in 1997 and currently serves as the Vice President of
Product Excellence at the Endoscopy Division, located in the Silicon Valley. Bryan has
a strong passion for technology, people and teams. Through experiences in
manufacturing engineering, operations management, R&D, quality and regulatory
Bryan has built an expertise in solving tough user needs by driving innovation from
numerous sources and industries into the medical device arena. He received his BS in
Engineering Science from Montana Tech and MBA from Santa Clara University.
Ron Leuty has been a reporter or editor for more than 25 years, including editor of
two startup business journals and business editor of the Prague Post in the Czech
Republic. He has covered biotech for the San Francisco Business Times for nine
years. He also has covered banking, manufacturing, law and sports business.
Brian Otis, PhD is a CTO at Verily Life Sciences and a Research Associate Professor at
the University of Washington, Seattle. He received a B.S. in electrical engineering
from the University of Washington, Seattle, and a M.S. and Ph.D. degree in electrical
engineering from the University of California, Berkeley. He joined the faculty of the
University in 2005 where he founded a chip design research lab that develops tiny,
low power wireless chips for a variety of applications (neural recording, implantable
devices, wearable onbody wireless sensors, environmental monitoring, etc). He has
previously held positions at Intel Corporation and Agilent Technologies and has been
with Google Inc since 2012. He was a founder of Google [x]’s smart contact lens
project and leads the medical device efforts at Verily Life Sciences. He has served as
a member of the Technical Program Committee of the International SolidState
Circuits Conference (ISSCC) and Associate Editor of the Journal of Solid State Circuits
(JSSC). His research interests include low power SoC design, exploring limitations of
power and size of wireless systems, and the realization of novel biomedical devices.
Firat Yazicioglu, PhD, is the head of Neuromodulation Devices at GSK Bioelectronics
R&D and responsible for the development of implantable devices and creation of new
technologies for implantable devices. He received his PhD degree from KU Leuven in
Belgium and worked 13 years at imec, a Belgian technology research institute, where
he led the research on biomedical circuits and systems for wearable and implantable
applications. He has developed technologies for several biomedical devices including
wireless cardiac monitoring patches, wearable EEG recording headsets, and
implantable neural probes for high density recording of neural activity.
Reza Zadno, PhD is an Innovation Advisor to Novartis Venture Fund (NVF) located in
San Francisco, CA, USA. Reza is a serial entrepreneur focused on sourcing new
investments particularly in the area of medical devices. Reza was the founder,
President and CEO of Visiogen (a former NVF-portfolio company acquired by Abbott-
Medical Optics) and co-founder of PercuSurge (acquired by Medtronic). Reza is also
currently Executive in Residence at InterWest Partners. Prior to joining InterWest in
2012, Reza was a Venture Partner at New Leaf Venture Partners and, previously, an
Entrepreneur in Residence at Three Arch Partners. Earlier in his career, he was with
Cardiac Pathways (acquired by Boston Scientific) and with Raychem Corporation, now
Tyco. Reza holds a Ph.D. from Ecole des Mines de Paris and has filed more than 100
24
U.S. patents. He serves on the boards of the following non-NVF companies, Carbylan,
Gobiquity, Invuity, On Demand Therapeutics and Oraya Therapeutics.
***************************************************************
PBSS Workshop, Monday, June 27, 2016
Workshop
Topic: “UHPLC in Biopharmaceutical Analysis: Benefits, Practices, Issues and
Implementation”
Speakers: Dr. Michael W. Dong, MWD Consulting
Date and Time: Monday, June 27, 2016, 8:45-12:30
Registration fee (US$): (USD$)Regular: $125; For vendor-show reps: $25; For unemployed
& students: $20; For major-sponsor rep (incl lunch): $0;
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor: (1)Agilent
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:6/23/2016 (it will close sooner if the seating cap is reached)
About the Topic
Ultra-high-pressure liquid chromatography (UHPLC) is the new standard HPLC platform
delivering higher performance with small-particle columns used on low-dispersion systems
with pressure limits of 15,000 – 23,000 psi. This intermediate-level 1/2-day training
workshop will provide a critical overview the fundamental concepts, benefits, potential
issues, and best practices of UHPLC in pharmaceutical analysis of small molecule drugs and
recombinant biologics (monoclonal antibodies, mAbs)
Who Should Attend
This workshop is intended for analysts, managers, and researchers wishing to have a
thorough understanding the fundamentals and practices of UHPLC in pharmaceutical
analysis. A basic knowledge of HPLC is assumed and some practical hands-on experience is
highly recommended.
Workshop Agenda
UHPLC 1: Concept and Benefits
1. Overview and perspectives, Glossary, the modern HPLC platform with higher
performance, UHPLC concepts (the need for high pressure, void volume, peak
volume, instrumental bandwidth), UV flow cell design, dwell volume.
2. Benefits and case studies: Very fast separations with good resolution, very high
resolution analysis of complex samples, facilitating rapid method development,
flexibility to customize resolution, a modernized generic method for most drugs, a
greener HPLC platform.
UHPLC 2: Potential Issues, Practices, and implementation
1. Potential issues and how to mitigate (viscous heating, operating nuances,
compatibility to existing methods, injection precision, detector sensitivity vs. mixing
volumes.
2. Method translation (transfer) issues: method portability, method conversion
(translation), “What is method transfer?”, need for partial method validation, case
studies.
3. How to transition from HPLC to UHPLC, end-fittings, system performance tradeoffs,
Myths in UHPLC, references.
Learning Outcomes UHPLC in Biopharmaceutical Analysis
25
The attendee will learn the benefits, best practices and potential issues of UHPLC in
pharmaceutical analysis including method translation and how to get started in UHPLC.
About the Speakers
Dr. Michael W. Dong is a principal consultant in MWD Consulting focusing on consulting and
training services on HPLC/UHPLC, pharmaceutical analysis and drug quality. He was
formerly Senior Scientist in Analytical Chemistry and Quality Control at Genentech,
Research Director at Synomics Pharma, Research Fellow at Purdue Pharma, and Senior Staff
Scientist at Applied Biosystems / Perkin-Elmer. He holds a Ph.D. in Analytical Chemistry
from the City University of New York, and a certificate in Biotechnology from U. C. Santa
Cruz. He has 100+ publications including a bestselling book on chromatography (Modern
HPLC for Practicing Scientists). He is an editorial advisory board member of LCGC magazine
and American Pharmaceutical Review.
*************************************************************
PBSS, Friday MidDay, July 29, 2016
Seminar luncheon
Topic: “CRISPR gene editing platform development for drug discovery and validation”
Speakers: Benjamin Haley, PhD (Genentech)
Organizers:
Date: Friday, July 29, 2016, 11:00-13:30
Registration fee (US$): (USD$);
Location: SF Bay Area: Foster City Crowne Plaza
Major Sponsor:
Vendor show vendors registered to date:
Registration: http://www.PBSS.org
Registration deadline:7/27/2016 (it will close sooner if the seating cap is reached)
******************************************************************
Bio2Device Group, Tuesday Evening, August 9, 2016
Topic: TBA
Speaker: Dr. Allison Dupuy, Partner, Simon-Kucher
Date and Time: Tuesday, Aug. 9, 2016, 6:00 pm
Date and Time: Tuesday, Oct. 13, 2015, 6:00pm
Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA
Cost:
$6 - Students/In-transition - Members only
$11 - Early-bird Registration - Members only
$20 - Late Registration and Non-Members
$25 - Walk-ins (as space permits)
Register at www.Bio2DeviceGroup.org
Speaker Bio
Dr. Allison Dupuy is a Partner in the Life Sciences division of Simon-Kucher & Partners in
San Francisco and leads the company’s life sciences practice on the west coast of the
US. She joined the team in San Francisco in August 2012 after spending 5 years in
Simon-Kucher’s Boston office.
In her work at Simon-Kucher, she focuses on strategic pharmaceutical marketing, value-
to-customer, market entry strategies, pricing and market access strategies, innovative
pricing strategies, product lifecycle strategies, licensing and valuation, market
forecasting and value communication, including global value story development and
implementation. She is a trusted advisor of leading pharmaceutical and biotech
26
companies across a wide range of therapeutic areas in all major healthcare markets
across the globe.
Dr. Dupuy received her Ph.D. and M.Phil. in Molecular Biophysics and Biochemistry from
Yale University and a B.A. in Physics with honors from Wellesley College where she was
a Goldwater Scholar and a Schiff Fellow.
She is the author and coauthor of several scientific publications and has research
experience in theoretical and experimental physics, biophysics, cell biology, cancer
biology, genomics, proteomics, bioinformatics and biochemistry.
****************************************************************
JLABS Meet with…Path, Thursday Morning, Sept. 8, 2016
Event: Meet with Path
PATH Participating Representative:
David Shoultz, Ph.D., MS, MBA | Global Program Leader, Drug Development and
Devices and Tools, PATH
Date and Time: Thursday, September 8, 2016 from 10:30 AM to 1:00 PM (PDT)
Agenda:
10:30am | Registration Opens and Networking
11:00am | Presentation and Q&A
11:45am | Networking Lunch
1:00-5:00pm | One-on-one Meetings*
*Companies must have applied for a one-on-one meeting ahead of time and be
approved. The application period ends on August 3rd.
Fees:
Presentation
$25 | General Public
$35 | Onsite
Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of
one-on-one meeting status. Pre-registration to attend the presentation, Q&A, and
lunch will remain open until noon on September 7th (or sold out).
One-on-One Meeting
FREE | Application
FREE | Accepted Companies
Companies must have applied for a one-on-one meeting ahead of time. The one-on-
one application period ends on August 3rd. Your application will be reviewed and you
will be notified of acceptance on August 19th. Acceptance of one-on-one meetings is
not guaranteed as all applications must be approved.
Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd., 3rd Floor,
South San Francisco, CA
Register at http://www.eventbrite.com/e/meet-with-path-tickets-
23921043485?aff=weekly
Description of PATH
PATH is the leader in global health innovation. An international nonprofit
organization, PATH saves lives and improves health, especially among women and
children. PATH accelerates innovation across five platforms - vaccines, drugs,
diagnostics, devices, and system and service innovations - that harness their
entrepreneurial insight, scientific and public health expertise, and passion for health
equity. By mobilizing partners around the world, PATH takes innovation to scale,
27
working alongside countries primarily in Africa and Asia to tackle their greatest
health needs.
PATH works with companies to create market-based solutions through tailored
partnership opportunities that deliver measurable impact. PATH matches each
company's resources and expertise with their unique strengths to accelerate the next
generation of lifesaving innovations, creating better health and opportunity for all.
Partnering with PATH is a smart investment that can yield significant social impact.
Companies choose to work with PATH because of their:
Focus on high-impact, large-scale, sustainable approaches - and measurable results.
Proven technical and market expertise.
History of successful partnership with the private sector that dates from their
founding in 1977.
Extensive in-country networks in more than 70 countries around the world.
International reputation as a trusted and influential convener and translator and their
ability to mobilize partners across borders, sectors, and disciplines.
Major funders include the Bill & Melinda Gates Foundation; the US government; other
governments, other nonprofit organizations, and multilateral agencies such as the
World Health Organization; individuals; and interest from investments.
Headquartered in Seattle, Washington, PATH has 1,300 employees, 1,400 partners
worldwide, and an annual budget of US$300 million. Visit www.path.org for more
details. If your company has technologies with applications in low- and middle-
income countries, apply to meet one-on-one with PATH.
Dr. David Shoultz, program leader, Drug Development and Devices and Tools
programs at PATH, will be in attendance on Thursday, September 8, to provide an
overview presentation on PATH's areas of interest and keys to solving global health
issues.
David and other PATH representatives will meet with a handful of preapproved
applicants after the presentation. To be considered for a one-on-one meeting,
complete the information required here.
Speaker Bio
David Shoultz, Ph.D., MS, MBA, directs two of PATH's product development
programs: the Drug Development program, which seeks to discover, develop, and
deliver safe, effective, and affordable treatments for neglected diseases, and the
Devices and Tools program, which focuses on advancing appropriate, affordable, and
accessible technologies to improve the health of underserved populations.
Prior to joining PATH in 2014, Dr. Shoultz served as the director of grantee and
partner engagement and as a member of the leadership team at the Bill & Melinda
Gates Foundation. In this role, he led an effort to strengthen the foundation's
relationships with its partner organizations to facilitate ongoing interactions and help
achieve maximum impact. Previously, he served as a deputy director in the
foundation's Global Health Program, Infectious Disease, where he was central to
strategy, planning, and management for four strategic program teams, including
malaria, enteric diseases, pneumonia, and the neglected tropical diseases.
Prior to his roles at the foundation, Dr. Shoultz worked as a member of the senior
management team for a number of clinical research organizations participating in the
development of new medicines, including PPD Development, PRA International, and
Biomedical Systems. He has been a member of the affiliate faculty for the
28
departments of Global Health and Epidemiology at the University of Washington since
2000 and sits on the board of the Geneva Foundation, where he also serves as the
inaugural chair of the Scientific Advisory Committee. Dr. Shoultz earned his Ph.D.
and MS from the School of Public Health and Community Medicine at the University of
Washington, where he also obtained his BSN. He holds an MBA from the Albers
School of Business and Economics at Seattle University, where he is a faculty
member in the Executive MBA Program.
David Shoultz leads our work in drug development and in devices and tools.